Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Lim

Showing results (1-10 of 467) with videos related to

Pageof 47
Sort By:
Neuro-Oncology|May 13, 2015
Immunotherapy for glioblastoma: are we finally getting closer?Michael Lim
Reproductive Health Matters|June 9, 2005
Fetal discourses and the politics of the wombMichael Lim Tan
Neuro-Oncology|June 22, 2019
Bespoke immunotherapy: how close are we?Christina Jackson, Michael Lim
Oncotarget|March 1, 2019
Why is immunotherapy for glioblastoma "Lag"-gingDimitrios Mathios, Michael Lim
Neuro-Oncology|October 9, 2021
Checkpoint blockade in recurrent meningiomas: Lessons for future managementAyush Pant, Michael Lim
Operative Neurosurgery (Hagerstown, Md.)|January 14, 2021
In Reply: Absence of Ischemic Injury After Sacrificing the Superior Petrosal Vein During Microvascular DecompressionYuanxuan Xia, Michael Lim
Proceedings of the National Academy of Sciences of the United States of America|September 6, 2023
Overcoming EGFR inhibitor resistance in Glioblastoma by targeting co-amplified genesAyush Pant, Michael Lim
Cancer Journal (Sudbury, Mass.)|September 27, 2021
The Challenges and Future of Immunotherapy for GliomasAdela Wu, Michael Lim
Nature Medicine|May 15, 2023
Advancing combination therapy for recurrent glioblastomaAdela Wu, Michael Lim
Cancers|February 25, 2023
CAR-T Therapy in GBM: Current Challenges and Avenues for ImprovementAyush Pant, Michael Lim
Pageof 47

Showing results (1-10 of 467) with videos related to

Sort By:
Pageof 47
Neuro-Oncology|May 13, 2015
Immunotherapy for glioblastoma: are we finally getting closer?Michael Lim
Reproductive Health Matters|June 9, 2005
Fetal discourses and the politics of the wombMichael Lim Tan
Neuro-Oncology|June 22, 2019
Bespoke immunotherapy: how close are we?Christina Jackson, Michael Lim
Oncotarget|March 1, 2019
Why is immunotherapy for glioblastoma "Lag"-gingDimitrios Mathios, Michael Lim
Neuro-Oncology|October 9, 2021
Checkpoint blockade in recurrent meningiomas: Lessons for future managementAyush Pant, Michael Lim
Operative Neurosurgery (Hagerstown, Md.)|January 14, 2021
In Reply: Absence of Ischemic Injury After Sacrificing the Superior Petrosal Vein During Microvascular DecompressionYuanxuan Xia, Michael Lim
Proceedings of the National Academy of Sciences of the United States of America|September 6, 2023
Overcoming EGFR inhibitor resistance in Glioblastoma by targeting co-amplified genesAyush Pant, Michael Lim
Cancer Journal (Sudbury, Mass.)|September 27, 2021
The Challenges and Future of Immunotherapy for GliomasAdela Wu, Michael Lim
Nature Medicine|May 15, 2023
Advancing combination therapy for recurrent glioblastomaAdela Wu, Michael Lim
Cancers|February 25, 2023
CAR-T Therapy in GBM: Current Challenges and Avenues for ImprovementAyush Pant, Michael Lim
Pageof 47